Skip to main content
Erschienen in: Pathology & Oncology Research 4/2009

01.12.2009 | Original Paper

TLR9 Signaling Promotes Tumor Progression of Human Lung Cancer Cell In Vivo

verfasst von: Tao Ren, Lin Xu, Shuxian Jiao, Yanying Wang, Yingyun Cai, Yongjie Liang, Ya Zhou, Hong Zhou, Zhenke Wen

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Toll like receptor 9 (TLR9) was identified mainly in cells of the immune system, and CpG oligonucleotides (CpG ODN), which induces signaling through TLR9, are currently under investigation as adjuvants in clinical therapies against cancer. However, accumulating data suggested that functional TLR9 was also expressed in tumor cells and the effects of TLR9 signaling on the progression of tumor cells remain undefined. Our previous study demonstrated that the TLR9 signaling could significantly enhance the metastatic potential of human lung cancer cells in vitro. Here we carefully evaluated the direct effect of TLR9 signaling on tumor progression of human lung cancer cells in vitro and in vivo. We observed that TLR9 agonist CpG ODN could robustly enhance the tumor progression of 95D cells which expressed high level of TLR9 in nude mice. Furthermore, the CpG ODN could effectively induce the proliferation and IL-10 secretion of 95D cells in vitro. Finally, we demonstrated that CpG ODN could significantly elevate the tumor progression of TLR9 modifying 95C cells in vitro and in vivo, which could be dramatically abrogated by the inhibitory CpG ODN. Our findings indicated that the TLR9 signaling could promote the tumor progression of human tumor cells, which might provide novel insight into the implications for CpG based anti-tumor therapies.
Literatur
1.
Zurück zum Zitat Werling D, Jungi TW (2003) TOLL-like receptors linking innate and adaptive immune response. Vet Immunol Immunopathol 91:1–12CrossRefPubMed Werling D, Jungi TW (2003) TOLL-like receptors linking innate and adaptive immune response. Vet Immunol Immunopathol 91:1–12CrossRefPubMed
2.
3.
Zurück zum Zitat Aliprantis AO, Yang RB, Mark MR et al (1999) Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285:736–739CrossRefPubMed Aliprantis AO, Yang RB, Mark MR et al (1999) Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285:736–739CrossRefPubMed
4.
Zurück zum Zitat Alexopoulou L, Holt AC, Medzhitov R et al (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll like receptor 3. Nature 413:732–738CrossRefPubMed Alexopoulou L, Holt AC, Medzhitov R et al (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll like receptor 3. Nature 413:732–738CrossRefPubMed
5.
Zurück zum Zitat Poltorak A, He X, Smirnova I et al (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085–2088CrossRefPubMed Poltorak A, He X, Smirnova I et al (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085–2088CrossRefPubMed
6.
Zurück zum Zitat Hemmi H, Takeuchi O, Kawai T et al (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408:740–745CrossRefPubMed Hemmi H, Takeuchi O, Kawai T et al (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408:740–745CrossRefPubMed
7.
Zurück zum Zitat Muzio M, Natoli G, Saccani S et al (1998) The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 187:2097–2101CrossRefPubMed Muzio M, Natoli G, Saccani S et al (1998) The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 187:2097–2101CrossRefPubMed
8.
Zurück zum Zitat Vollmer J, Weeratna R, Payette P et al (2004) Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34:251–262CrossRefPubMed Vollmer J, Weeratna R, Payette P et al (2004) Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34:251–262CrossRefPubMed
9.
Zurück zum Zitat Kraft AR, Krux F, Schimmer S et al (2007) CpG Oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection. Blood 109:2982–2984PubMed Kraft AR, Krux F, Schimmer S et al (2007) CpG Oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection. Blood 109:2982–2984PubMed
10.
Zurück zum Zitat Chaudhry UI, Kingham TP, Plitas G et al (2006) Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res 66:497–504CrossRef Chaudhry UI, Kingham TP, Plitas G et al (2006) Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res 66:497–504CrossRef
11.
Zurück zum Zitat Roman M, Martin-Orozco E, Goodman JS et al (1997) Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 3:849–854CrossRefPubMed Roman M, Martin-Orozco E, Goodman JS et al (1997) Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 3:849–854CrossRefPubMed
12.
Zurück zum Zitat O’Keeffe M, Grumont RJ, Hochrein H et al (2005) Distinct roles for the NF-kappaB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals. Blood 106:3457–3464CrossRefPubMed O’Keeffe M, Grumont RJ, Hochrein H et al (2005) Distinct roles for the NF-kappaB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals. Blood 106:3457–3464CrossRefPubMed
13.
Zurück zum Zitat Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94:459–473CrossRefPubMed Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94:459–473CrossRefPubMed
14.
Zurück zum Zitat Sparwasser T, Vabulas RM, Villmow B et al (2000) Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 30:3591–3597CrossRefPubMed Sparwasser T, Vabulas RM, Villmow B et al (2000) Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 30:3591–3597CrossRefPubMed
15.
Zurück zum Zitat Heckelsmiller K, Beck S, Rall K et al (2002) Combined dendritic cell-and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 32:3235–3245CrossRefPubMed Heckelsmiller K, Beck S, Rall K et al (2002) Combined dendritic cell-and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 32:3235–3245CrossRefPubMed
16.
Zurück zum Zitat Okamoto M, Sato M (2003) Toll-like receptor signaling in anti-cancer immunity. J Med Invest 50:9–24PubMed Okamoto M, Sato M (2003) Toll-like receptor signaling in anti-cancer immunity. J Med Invest 50:9–24PubMed
17.
Zurück zum Zitat Wooldridge JE, Weiner GJ (2003) CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Curr Opin Oncol 15:440–445CrossRefPubMed Wooldridge JE, Weiner GJ (2003) CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Curr Opin Oncol 15:440–445CrossRefPubMed
18.
Zurück zum Zitat Belvin MP, Anderson KV (1996) A conserved signaling pathway: the Drosophila toll-dorsal pathway. Annu Rev Cell Dev Biol 12:393–416CrossRefPubMed Belvin MP, Anderson KV (1996) A conserved signaling pathway: the Drosophila toll-dorsal pathway. Annu Rev Cell Dev Biol 12:393–416CrossRefPubMed
20.
Zurück zum Zitat Coussens LM, Werb Z (2001) Inflammatory cells and cancer: think different!. J Exp Med1 93:F23–26CrossRef Coussens LM, Werb Z (2001) Inflammatory cells and cancer: think different!. J Exp Med1 93:F23–26CrossRef
21.
Zurück zum Zitat Ren T, Wen ZK, Liu ZM et al (2007) Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther 6:1704–1709PubMedCrossRef Ren T, Wen ZK, Liu ZM et al (2007) Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther 6:1704–1709PubMedCrossRef
22.
Zurück zum Zitat Lubin I, Segall H, Marcus H et al (1994) Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood 83:2368–2381PubMed Lubin I, Segall H, Marcus H et al (1994) Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood 83:2368–2381PubMed
23.
Zurück zum Zitat Tsushima F, Tanaka K, Otsuki N et al (2006) Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol 42:268–274CrossRefPubMed Tsushima F, Tanaka K, Otsuki N et al (2006) Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol 42:268–274CrossRefPubMed
24.
Zurück zum Zitat Wang CC, Zeng Q, Hwang LA et al (2006) Mouse lymphomas caused by an intron-splicing donor site deletion of the FasL gene. Biochem Biophys Res Commun 349:50–58CrossRefPubMed Wang CC, Zeng Q, Hwang LA et al (2006) Mouse lymphomas caused by an intron-splicing donor site deletion of the FasL gene. Biochem Biophys Res Commun 349:50–58CrossRefPubMed
25.
Zurück zum Zitat Gazzinelli RT, Denkers EY (2006) Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat Rev Immunol 6:895–906CrossRefPubMed Gazzinelli RT, Denkers EY (2006) Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat Rev Immunol 6:895–906CrossRefPubMed
26.
Zurück zum Zitat Creagh EM, O’Neill LA (2006) TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 27:352–357CrossRefPubMed Creagh EM, O’Neill LA (2006) TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 27:352–357CrossRefPubMed
27.
Zurück zum Zitat Droemann D, Albrecht D, Gerdes J et al (2005) Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 6:1CrossRefPubMed Droemann D, Albrecht D, Gerdes J et al (2005) Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 6:1CrossRefPubMed
28.
Zurück zum Zitat Jarrousse V, Quereux G, Marques-Briand S et al (2006) Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Eur J Dermatol 16:636–641PubMed Jarrousse V, Quereux G, Marques-Briand S et al (2006) Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Eur J Dermatol 16:636–641PubMed
29.
Zurück zum Zitat Huang B, Zhao J, Unkeless JC et al (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27:218–224CrossRefPubMed Huang B, Zhao J, Unkeless JC et al (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27:218–224CrossRefPubMed
30.
Zurück zum Zitat Merrell MA, Ilvesaro JM, Lehtonen N et al (2006) Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 4:437–447CrossRefPubMed Merrell MA, Ilvesaro JM, Lehtonen N et al (2006) Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 4:437–447CrossRefPubMed
31.
Zurück zum Zitat Kelly MG, Alvero AB, Chen R et al (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66:3859–3868CrossRefPubMed Kelly MG, Alvero AB, Chen R et al (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66:3859–3868CrossRefPubMed
33.
Zurück zum Zitat Bermudez-Morales VH, Gutierrez LX, Alcocer-Gonzalez JM et al (2008) Correlation Between IL-10 Gene Expression and HPV Infection in Cervical Cancer: A Mechanism for Immune Response Escape. Cancer Invest 16:1 [Epub ahead of print] Bermudez-Morales VH, Gutierrez LX, Alcocer-Gonzalez JM et al (2008) Correlation Between IL-10 Gene Expression and HPV Infection in Cervical Cancer: A Mechanism for Immune Response Escape. Cancer Invest 16:1 [Epub ahead of print]
34.
Zurück zum Zitat Decker T, Schneller F, Sparwasser T et al (2000) Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95:999–1006PubMed Decker T, Schneller F, Sparwasser T et al (2000) Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95:999–1006PubMed
Metadaten
Titel
TLR9 Signaling Promotes Tumor Progression of Human Lung Cancer Cell In Vivo
verfasst von
Tao Ren
Lin Xu
Shuxian Jiao
Yanying Wang
Yingyun Cai
Yongjie Liang
Ya Zhou
Hong Zhou
Zhenke Wen
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2009
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-009-9162-0

Weitere Artikel der Ausgabe 4/2009

Pathology & Oncology Research 4/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.